Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis

verfasst von: Ou Huang, Min Jiang, Xi Zhang, Xiaosong Chen, Jiayi Wu, Kunwei Shen

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Many studies were published to assess the association between FASLG T844C polymorphism and susceptibility to breast cancer, but the data were controversial. A meta-analysis was performed to assess the association comprehensively. We performed a comprehensive search in PubMed, Embase, and Web of Science to find eligible studies. Six studies with a total of 6,784 participants were finally included into the meta-analysis. There were a total of 3,382 cases with breast cancer and 3,402 controls in those six studies. Odds ratio (OR) with 95 % confidence interval (95 %CI) was used to evaluate the association. Overall, there was an obvious association between FASLG T844C polymorphism and breast cancer under all four contrast models (for C versus T: OR = 1.26, 95 %CI 1.05–1.50, P OR = 0.011; for CC versus TT: OR = 1.42, 95 %CI 1.11–1.81, P OR = 0.005; for CC versus TT/TC: OR = 1.41, 95 %CI 1.06–1.88, P OR = 0.019; for CC/TC versus TT: OR = 1.16, 95 %CI 1.01–1.33, P OR = 0.038). In the subgroup analysis by ethnicity, there was an obvious association between FASLG T844C polymorphism and breast cancer in Asians, but there was no obvious association in Caucasians. The meta-analysis suggests that there is an association between FASLG T844C polymorphism and susceptibility to breast cancer, especially in Asians.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10:205–12.PubMedCrossRef Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10:205–12.PubMedCrossRef
4.
Zurück zum Zitat Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.PubMedCrossRef Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.PubMedCrossRef
5.
Zurück zum Zitat Campa D, McKay J, Sinilnikova O, Husing A, Vogel U, Hansen RD, et al. Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk. Breast Cancer Res Treat. 2009;118:565–74.PubMedCrossRef Campa D, McKay J, Sinilnikova O, Husing A, Vogel U, Hansen RD, et al. Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk. Breast Cancer Res Treat. 2009;118:565–74.PubMedCrossRef
6.
Zurück zum Zitat van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71–88.CrossRef van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71–88.CrossRef
7.
Zurück zum Zitat Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz). 2013;61:43–58.CrossRef Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz). 2013;61:43–58.CrossRef
8.
Zurück zum Zitat Denis CJ, Deiteren K, Hendriks D, Proost P, Lambeir AM. Carboxypeptidase m in apoptosis, adipogenesis and cancer. Clin Chim Acta. 2013;415:306–16.PubMedCrossRef Denis CJ, Deiteren K, Hendriks D, Proost P, Lambeir AM. Carboxypeptidase m in apoptosis, adipogenesis and cancer. Clin Chim Acta. 2013;415:306–16.PubMedCrossRef
9.
Zurück zum Zitat Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol. 2009;647:64–93.PubMedCrossRef Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol. 2009;647:64–93.PubMedCrossRef
10.
Zurück zum Zitat Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:85–101.PubMedCrossRef Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:85–101.PubMedCrossRef
11.
Zurück zum Zitat Lettau M, Paulsen M, Schmidt H, Janssen O. Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol. 2011;90:456–66.PubMedCrossRef Lettau M, Paulsen M, Schmidt H, Janssen O. Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol. 2011;90:456–66.PubMedCrossRef
12.
Zurück zum Zitat Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010;49:944–50.PubMedCrossRef Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010;49:944–50.PubMedCrossRef
13.
Zurück zum Zitat Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, et al. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res. 2011;17:5991–9.PubMedCrossRef Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, et al. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res. 2011;17:5991–9.PubMedCrossRef
14.
Zurück zum Zitat Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004;96:1478–9. author reply 1479.PubMedCrossRef Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004;96:1478–9. author reply 1479.PubMedCrossRef
15.
Zurück zum Zitat Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28:2548–51.PubMedCrossRef Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28:2548–51.PubMedCrossRef
16.
Zurück zum Zitat Zhang B, Sun T, Xue L, Han X, Lu N, Shi Y, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28:1067–73.PubMedCrossRef Zhang B, Sun T, Xue L, Han X, Lu N, Shi Y, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28:1067–73.PubMedCrossRef
17.
Zurück zum Zitat Mahfoudh W, Bouaouina N, Gabbouj S, Chouchane L. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the tunisian population. Hum Immunol. 2012;73:932–8.PubMedCrossRef Mahfoudh W, Bouaouina N, Gabbouj S, Chouchane L. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the tunisian population. Hum Immunol. 2012;73:932–8.PubMedCrossRef
18.
Zurück zum Zitat Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3:625–8.PubMedCentralPubMed Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3:625–8.PubMedCentralPubMed
19.
Zurück zum Zitat Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer—pilot study of 134 cases. PLoS One. 2013;8:e53075.PubMedCentralPubMedCrossRef Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer—pilot study of 134 cases. PLoS One. 2013;8:e53075.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
21.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
22.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
23.
Zurück zum Zitat Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
24.
Zurück zum Zitat Gong WF, Zhong JH, Xiang BD, Ma L, You XM, Zhang QM, et al. Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases. PLoS One. 2013;8:e60108.PubMedCentralPubMedCrossRef Gong WF, Zhong JH, Xiang BD, Ma L, You XM, Zhang QM, et al. Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases. PLoS One. 2013;8:e60108.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Yang Z, Shen J, Cao Z, Wang B. Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk. Breast Cancer Res Treat. 2013;139:267–75.PubMedCrossRef Yang Z, Shen J, Cao Z, Wang B. Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk. Breast Cancer Res Treat. 2013;139:267–75.PubMedCrossRef
26.
Zurück zum Zitat Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian HP, et al. FASLG polymorphism is associated with cancer risk. Eur J Cancer. 2009;45:2574–8.PubMedCrossRef Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian HP, et al. FASLG polymorphism is associated with cancer risk. Eur J Cancer. 2009;45:2574–8.PubMedCrossRef
Metadaten
Titel
FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis
verfasst von
Ou Huang
Min Jiang
Xi Zhang
Xiaosong Chen
Jiayi Wu
Kunwei Shen
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1145-9

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.